'Y­ou be­trayed that du­ty': For­mer con­gress­man Chris Collins sen­tenced to 26 months in jail for in­sid­er trad­ing

4 years ago
People

Bernie Sanders goes af­ter Bio­Mar­in's shot at a record drug price, threat­en­ing to break the patent

4 years ago
People
Bioregnum

Rev­o­lu­tion Med shoots for $100M+ IPO — and di­vulges some se­crets about that Warp Dri­ve buy­out

4 years ago
R&D

At #JPM20, two CEOs, two rad­i­cal­ly dif­fer­ent ther­a­pies, and a fight to chase down sick­le cell

4 years ago
R&D
Cell/Gene Tx

No­vo Nordisk's block­buster Ozem­pic wins FDA la­bel boost with CV in­di­ca­tion

4 years ago
R&D

First Chi­nese biotech on Nas­daq in two years draws $104M

4 years ago
Financing

Bio­Marin ex­ecs dis­cuss some eye-pop­ping num­bers for the price of val­rox — but haven't we heard this be­fore?

4 years ago
R&D

#JPM20: Five years af­ter first PC­SK9, No­var­tis goes for win as Sanofi moves on, Am­gen sal­vages what's left

4 years ago
R&D

Neon Ther­a­peu­tics makes one last re­treat, sell­ing it­self cheap in a bar­gain base­ment M&A deal

4 years ago
Deals
R&D

#JPM20: Af­ter a year of NASH col­laps­es, all eyes on two biotechs

4 years ago
R&D
In Focus

Gala­pa­gos beefs up its fi­bro­sis pipeline, las­so­ing 4 more pro­grams and tak­ing a stake in small Cana­di­an part­ner

4 years ago
Deals

Nek­tar aban­dons opi­oid drug af­ter a unan­i­mous 27-0 re­buff from FDA ad­comm

4 years ago
R&D

Four years af­ter 'moon­shot' launch, Patrick Soon-Sh­iong has a big re­veal: a sin­gle pa­tient

4 years ago
R&D

Still to be ap­proved in­clisir­an gets red car­pet treat­ment by UK's NHS in deal with No­var­tis

4 years ago
Deals

New Adap­ti­m­mune man­age­ment scores con­fi­dence boost with up to $897M+ Astel­las deal

4 years ago
Deals

Amar­in's Vas­cepa reigns supreme in fish oil bat­tle, as As­traZeneca's ri­val fiz­zles

4 years ago
R&D
Pharma

Bio­phar­ma ends decade with near-record in­vest­ment — but is it go­ing to the right places?

4 years ago
Financing

Alex­is Borisy has $200M to back a mar­ket-based plan aimed at cur­ing Amer­i­ca’s drug pric­ing ‘sick­ness’

4 years ago
Financing
Pharma

J&J plans to re­cruit a new gen­er­a­tion of 'bilin­gual' sci­en­tists for a re­search fa­cil­i­ty blue­print­ed for the boom­ing Bay Area

4 years ago
Pharma

That com­pa­ny su­ing Patrick Soon-Sh­iong for $1B? Some­one's try­ing to buy it for $1B

4 years ago
R&D

Black­stone plots $4.5B+ life sci­ences fund — and they've al­ready se­cured the bulk of it

4 years ago
Financing

Eli Lil­ly buys a Roche dis­card in $1.1B Der­mi­ra buy­out. Can they go toe-to-toe with the heavy­weight chal­lenger Dupix­ent?

4 years ago
Deals

Blue­print scores first FDA OK for a pre­ci­sion GIST can­cer drug, just ahead of a ri­val treat­ment. And the price is a big sur­prise

4 years ago
Pharma
FDA+

Mod­er­na CEO Ban­cel of­fers a thumbs-up on lat­est up­date for their CMV pro­gram — with block­buster hopes for what's ahead

4 years ago
R&D
First page Previous page 171172173174175176177 Next page Last page